Ambrx, a US-China Biotech, Raises $45 Million for Clinical Trials
publication date: Aug 5, 2016
Ambrx, a San Diego biopharma, closed a $45 million financing round that will be used for a Phase I trial of its lead candidate, ARX788, a treatment for HER2-positive breast cancer. Last year, Ambrx was acquired by a consortium of China pharmas and investment firms, including Fosun Pharma and WuXi AppTec, for an undisclosed price. The latest fundraising was led by US investors Apricot Capital and Northeast Securities Prosperity Healthcare Fund. It was joined by an all-China group including new investors Sinopharm Capital and Humanwell Healthcare Fund, and existing investors Fosun Pharma, HOPU Investments and Everbright Limited Healthcare. More details....
Stock Symbol: (SHA: 600196; HK: 02196)
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.